Acquired immunodeficiency syndrome
Drug research and approvals for acquired immunodeficiency syndrome: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 598 studies of acquired immunodeficiency syndrome are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 1 approved and 9 open orphan designations naming it.
- Recruiting worldwide: 598
- Trials authorized in Canada: 0
- FDA orphan approvals: 1
- EU medicines: 0
- Checkpoint+: Improving Access to HIV Prevention and Early Diagnosis Among Migrant Men Who Have Sex With Men, Trans…NCT07937631 · Not reported · Felix Perez Tejera · starts May 18, 2026
- Immunogenicity and Safety of Freeze-Dried Human Rabies Vaccine (Vero Cell) in Patients Infected With Human…NCT07932132 · Phase 4 · Liaoning Chengda Biotechnology CO., LTD · starts Aug 8, 2026
- C2001P-CS6: Testing the Feasibility of Different HPV Screening and Care Strategies for Women Living With HIVNCT07925307 · Not applicable · University of California, San Diego · starts Oct 16, 2026
- Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir AlafenamideNCT07921472 · Not reported · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida · starts May 19, 2026
- Multiple Interventions With Distinct Anti-reservoir Activities in People on Antiretroviral TreatmentNCT07903441 · Phase 2 · Federal University of São Paulo · starts Aug 1, 2026
- A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming…NCT07850609 · Phase 2 · Merck Sharp & Dohme LLC · starts Oct 27, 2026
- El Camino HIV Prevention and Care StudyNCT07834853 · Not applicable · American University · starts Jul 16, 2026
- The Gender Inclusive Sexuality Talks ProgramNCT07825571 · Not applicable · University of Pennsylvania · starts Jan 1, 2026
- Auricular Vagus Nerve Stimulation Mechanisms for HIV-Associated Peripheral NeuropathyNCT07822932 · Not applicable · University of Miami · starts Nov 1, 2026
Approved 3
- GanciclovirHuman herpesvirus 1 DNA polymerase inhibitor
- ValganciclovirHuman herpesvirus 1 DNA polymerase inhibitor
- Megestrol acetateProgesterone receptor agonist
Phase 3 12 of 30
- Tenofovir disoproxilHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- LamivudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- RitonavirHuman immunodeficiency virus type 1 protease inhibitor
- EfavirenzHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- CobicistatCytochrome P450 3A inhibitor
- LopinavirHuman immunodeficiency virus type 1 protease inhibitor
- ZidovudineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- DarunavirHuman immunodeficiency virus type 1 protease inhibitor
- Tenofovir alafenamideHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- ElvitegravirHuman immunodeficiency virus type 1 integrase inhibitor
- NevirapineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- TenofovirHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
Phase 2 12 of 25
- EtravirineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Nogapendekin alfa
- Lafuvitug
- DoxorubicinDNA topoisomerase II alpha inhibitor
- IsoniazidEnoyl-[acyl-carrier-protein] reductase inhibitor
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- OfatumumabB-lymphocyte antigen CD20 binding agent
- RituximabB-lymphocyte antigen CD20 binding agent
- TestosteroneAndrogen Receptor agonist
- VincristineTubulin inhibitor
- EthambutolArabinosyltransferase A inhibitor
- CholecalciferolVitamin D receptor agonist
Phase 1 or earlier 10
- VRC07-523LS
- PGT-121
- DapivirineHuman immunodeficiency virus type 1 reverse transcriptase inhibitor
- Arsenic trioxideThioredoxin reductase 1 inhibitor
- BusulfanDNA inhibitor
- MoxifloxacinTopoisomerase IV inhibitor
- AldesleukinInterleukin-2 receptor agonist
- AmprenavirHuman immunodeficiency virus type 1 protease inhibitor
- Tucidinostat
- Carbomer homopolymer type b (allyl pentaerythritol crosslinked)
How its trials ended
1,760 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 402 whose ending is known, 58% met their primary endpoint, 11% missed it and 31% stopped early.
- Completed, result not reported1,03459%
- Met its primary endpoint23313%
- Ongoing19511%
- Status unknown1297%
- Stopped: other or unclear784%
- Missed its primary endpoint432%
- Stopped: enrollment or feasibility181%
- Stopped: lack of efficacy101%
- Stopped: sponsor or business decision101%
- Stopped: funding8<1%
- Stopped: safety2<1%
| Mar 4, 1996 | Vitrasert ImplantTreatment of CMV retinitis in patients with acquired immunodeficiency syndrome. | Bausch & Lomb Surgical, Chiron Vision Products | Approved |
| Jul 17, 2002 | RubitecanTreatment of pediatric patients infected with human immunodeficiency virus and acquired immunodeficiency syndrome | SuperGen, Inc. | Designated |
| Mar 24, 1992 | HIV neutralizing antibodiesTreatment of acquired immunodeficiency syndrome. | Hemacare Corporation | Designated |
| Nov 21, 1989 | CD4 human truncated 369 AA polypeptideTreatment of acquired immunodeficiency syndrome. | SmithKline Beecham | Designated |
| Nov 20, 1989 | 3'-azido-2',3'dideoxyuridineTreatment of acquired immunodeficiency syndrome. | Berlex Laboratories, Inc. | Designated |
| Nov 20, 1989 | Recombinant soluble human CD4Treatment of acquired immunodeficiency syndrome. | Biogen, Inc. | Designated |
| Nov 15, 1988 | Interferon beta, recombinant humanTreatment of acquired immunodeficiency syndrome. | Berlex Laboratories, Inc. | Designated |
| Jun 22, 1988 | DideoxyinosineTreatment of acquired immunodeficiency syndrome. | Bristol-Myers Squibb | Designated |
| Nov 9, 1987 | Ammonium trichloro [dioxoethylene-O,O') tellurium (IV)Treatment of acquired immunodeficiency syndrome. | NPDC-AS101, Inc. | Designated |
| Jul 17, 1985 | Ammonium 21-tungsto-9-antimoniateTreatment of acquired immunodeficiency syndrome. | Rhone-Poulenc Rorer Pharm. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA